BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29474179)

  • 1. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
    Mizukami A; Kaise T; Van Kriekinge G
    Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
    Brown RE; Breugelmans JG; Theodoratou D; Bénard S
    Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic burden of HPV-related diseases in Singapore.
    Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
    Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
    Herse F; Reissell E
    Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
    Righolt CH; Pabla G; Mahmud SM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
    Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
    Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer.
    Shavit O; Raz R; Stein M; Chodick G; Schejter E; Ben-David Y; Cohen R; Arbel D; Shalev V
    Appl Health Econ Health Policy; 2012 Mar; 10(2):87-97. PubMed ID: 22201263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
    Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Khorprasert C; Taneepanichskul S
    Value Health; 2012; 15(1 Suppl):S29-34. PubMed ID: 22265063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
    Dasbach EJ; Insinga RP; Elbasha EH
    BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
    Insinga RP; Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands.
    van Ballegooijen M; Koopmanschap MA; Habbema JD
    Eur J Cancer; 1995 Sep; 31A(10):1672-6. PubMed ID: 7488423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
    Brisson M; Van de Velde N; De Wals P; Boily MC
    Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
    Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
    Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
    Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
    Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.